List of works - Kristian Reich

A 24-week multicentre, randomized, open-label, parallel-group study comparing the efficacy and safety of ixekizumab vs. fumaric acid esters and methotrexate in patients with moderate-to-severe plaque psoriasis naive to systemic treatment

scientific article published on 19 November 2019

A Topical Treatment Optimization Programme (TTOP) improves clinical outcome for calcipotriol/betamethasone gel in psoriasis: results of a 64-week multinational randomized phase IV study in 1790 patients (PSO-TOP).

scientific article

A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial

scientific article published on 30 December 2019

A new treatment option for paediatric psoriasis

scientific article published on 01 October 2020

A phase 4, randomised, head-to-head trial comparing the efficacy of subcutaneous injections of brodalumab to oral administrations of fumaric acid esters in adults with moderate-to-severe plaque psoriasis (CHANGE)

scientific article published on 16 September 2020

A variant of the CXCL11 gene may influence susceptibility to contact allergy, particularly in polysensitized patients

scientific article

Assessment of the effects of immunogenicity on the pharmacokinetics, efficacy and safety of tildrakizumab

scientific article published on 04 July 2019

Clinical meaningfulness of complete skin clearance in psoriasis.

scientific article

Clinical response of psoriasis to subcutaneous methotrexate correlates with inhibition of cutaneous T helper 1 and 17 inflammatory pathways

scientific article published on 01 July 2019

Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study.

scientific article published on 19 May 2017

Complete clearance and psoriasis area and severity index response for brodalumab and ustekinumab in AMAGINE-2 and -3

scientific article published on 14 July 2020

Consistent responses with guselkumab treatment in Asian and non-Asian patients with psoriasis: An analysis from VOYAGE 1 and VOYAGE 2

scientific article published on 20 October 2019

Continued treatment with secukinumab is associated with high retention or regain of response

scientific article published on 17 July 2019

Definition of psoriasis severity in routine clinical care: current guidelines fail to capture the complexity of long-term psoriasis management

scientific article published on 17 October 2018

Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials

scientific article published on 21 March 2020

Efficacy and safety of ixekizumab after switching from fumaric acid esters or methotrexate in patients with moderate-to-severe plaque psoriasis naïve to systemic treatment

scientific article published on 17 September 2020

Genetic factors in contact allergy--review and future goals

scientific article published on January 2011

Guselkumab improves work productivity in patients with moderate-to-severe psoriasis with or without depression and anxiety: results from the VOYAGE 2 comparator study versus adalimumab

scientific article published on 15 July 2019

Immunogenicity of biologic therapies in psoriasis Myths, facts and a suggested approach

scientific article published on 08 October 2020

Ixekizumab treatment for psoriasis: Integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3).

scientific article

Long-Term Efficacy of Certolizumab Pegol for the Treatment of Plaque Psoriasis: Three-Year Results from Two Randomised Phase 3 Trials (CIMPASI-1 and CIMPASI-2)

scientific article published on 11 July 2020

Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 Study

scientific article published on 10 September 2020

Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis

scientific article published on 8 June 2016

Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials

scientific article published on 14 September 2020

Reaching complete or near-complete resolution of psoriasis: benefit and risk considerations

scientific article

Safety of Tildrakizumab for Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Three Randomised Controlled Trials.

scientific article

Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studies

scientific article published on 01 May 2019

Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label OPTIMISE study

scientific article published on 08 September 2019

Secukinumab in pregnancy: outcomes in psoriasis, psoriatic arthritis and ankylosing spondylitis from the global safety database

scientific article published on 11 September 2018

Secukinumab is superior to fumaric acid esters in treating patients with moderate-to-severe plaque psoriasis who are naive to systemic treatments: results from the randomized controlled PRIME trial.

scientific article published on 5 June 2017

Secukinumab two weekly versus four weekly dosing in patients with plaque-type psoriasis: results from the randomized GAIN study

scientific article published on 11 July 2020

Sex-related impairment and patient needs/benefits in anogenital psoriasis: Difficult-to-communicate topics and their impact on patient-centred care

scientific article published on 01 July 2020

Super‐response to guselkumab treatment in patients with moderate‐to‐severe psoriasis: age, body weight, baseline Psoriasis Area and Severity Index, and baseline Investigator's Global Assessment scores predict complete skin clearance

scientific article published in 2022

The genetic basis for most patients with pustular skin disease remains elusive

scientific article published on 5 August 2017

The value of subcutaneous versus oral methotrexate - real-world data from the German psoriasis registry PsoBest

scientific article published on 21 November 2020

Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials.

scientific article

Time to relapse after tildrakizumab withdrawal in patients with moderate-to-severe psoriasis who were responders at week 28: post-hoc analysis through 64 weeks from reSURFACE 1 trial

scientific article published on 26 September 2020

Topology of psoriasis in routine care: results from high-resolution analysis of 2009 patients

scientific article published on 24 January 2019

List of works by Kristian Reich

A 24-week multicentre, randomized, open-label, parallel-group study comparing the efficacy and safety of ixekizumab vs. fumaric acid esters and methotrexate in patients with moderate-to-severe plaque psoriasis naive to systemic treatment

A Topical Treatment Optimization Programme (TTOP) improves clinical outcome for calcipotriol/betamethasone gel in psoriasis: results of a 64-week multinational randomized phase IV study in 1790 patients (PSO-TOP).

A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial

A new treatment option for paediatric psoriasis

A phase 4, randomised, head-to-head trial comparing the efficacy of subcutaneous injections of brodalumab to oral administrations of fumaric acid esters in adults with moderate-to-severe plaque psoriasis (CHANGE)

A variant of the CXCL11 gene may influence susceptibility to contact allergy, particularly in polysensitized patients

Assessment of the effects of immunogenicity on the pharmacokinetics, efficacy and safety of tildrakizumab

Clinical meaningfulness of complete skin clearance in psoriasis.

Clinical response of psoriasis to subcutaneous methotrexate correlates with inhibition of cutaneous T helper 1 and 17 inflammatory pathways

Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study.

Complete clearance and psoriasis area and severity index response for brodalumab and ustekinumab in AMAGINE-2 and -3

Consistent responses with guselkumab treatment in Asian and non-Asian patients with psoriasis: An analysis from VOYAGE 1 and VOYAGE 2

Continued treatment with secukinumab is associated with high retention or regain of response

Definition of psoriasis severity in routine clinical care: current guidelines fail to capture the complexity of long-term psoriasis management

Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials

Efficacy and safety of ixekizumab after switching from fumaric acid esters or methotrexate in patients with moderate-to-severe plaque psoriasis naïve to systemic treatment

Genetic factors in contact allergy--review and future goals

Guselkumab improves work productivity in patients with moderate-to-severe psoriasis with or without depression and anxiety: results from the VOYAGE 2 comparator study versus adalimumab

Immunogenicity of biologic therapies in psoriasis Myths, facts and a suggested approach

Ixekizumab treatment for psoriasis: Integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3).

Long-Term Efficacy of Certolizumab Pegol for the Treatment of Plaque Psoriasis: Three-Year Results from Two Randomised Phase 3 Trials (CIMPASI-1 and CIMPASI-2)

Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 Study

Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis

Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials

Reaching complete or near-complete resolution of psoriasis: benefit and risk considerations

Safety of Tildrakizumab for Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Three Randomised Controlled Trials.

Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studies

Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label OPTIMISE study

Secukinumab in pregnancy: outcomes in psoriasis, psoriatic arthritis and ankylosing spondylitis from the global safety database

Secukinumab is superior to fumaric acid esters in treating patients with moderate-to-severe plaque psoriasis who are naive to systemic treatments: results from the randomized controlled PRIME trial.

Secukinumab two weekly versus four weekly dosing in patients with plaque-type psoriasis: results from the randomized GAIN study

Sex-related impairment and patient needs/benefits in anogenital psoriasis: Difficult-to-communicate topics and their impact on patient-centred care

Super‐response to guselkumab treatment in patients with moderate‐to‐severe psoriasis: age, body weight, baseline Psoriasis Area and Severity Index, and baseline Investigator's Global Assessment scores predict complete skin clearance

The genetic basis for most patients with pustular skin disease remains elusive

The value of subcutaneous versus oral methotrexate - real-world data from the German psoriasis registry PsoBest

Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials.

Time to relapse after tildrakizumab withdrawal in patients with moderate-to-severe psoriasis who were responders at week 28: post-hoc analysis through 64 weeks from reSURFACE 1 trial

Topology of psoriasis in routine care: results from high-resolution analysis of 2009 patients